Bolt Biotherapeutics is a clinical-stage immuno-oncology company developing tumor-targeted therapies that leverage the power of the innate and adaptive immune systems. Bolt’s proprietary Boltbody™ Immune-stimulating Antibody Conjugate (ISAC) approach uses immunostimulants to engage and activate myeloid cells that directly kill tumor cells. This leads to the conversion of immunologically “cold” tumors to “hot” tumors.
Our lead candidate, BDC-1001, is a Boltbody ISAC comprised of a HER2-targeting biosimilar of trastuzumab conjugated to one of our proprietary TLR7/8 agonists for the treatment of patients with HER2-expressing solid tumors. We believe that our preliminary Phase 1/2 data from our ongoing clinical trial provide us with clinical proof of concept for our HER2 Boltbody ISAC approach.
Bolt is also advancing additional Boltbody ISAC product candidates targeting CEA and PD-L1.
April 10, 2021
Bolt Biotherapeutics Announces AACR 2021 Presentation of Boltbody™ Platform Mechanism of Action and Clinical Properties of Lead ISAC, BDC-1001Read More
April 8, 2021
Bolt Biotherapeutics to Present at 20th Annual Needham Virtual Healthcare ConferenceRead More
March 31, 2021
Bolt Biotherapeutics Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Business HighlightsRead More